* Health Catalyst Inc HCAT.OQ HCAT.O is expected to show
a
rise in quarterly revenue when it reports results on November
8.
* The South Jordan Utah-based company is expected to report
a
8.2% increase in revenue to $66.794 million from $61.74 million
a year ago, according to the mean estimate from 14 analysts,
based on Refinitiv data. The company's guidance on August 4
2022, for the period ended September 30, was for revenue between
$65.30 million and $68.30 million.
* Refinitiv's mean analyst estimate for Health Catalyst Inc
is
for a loss of 19 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 6
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Health
Catalyst
Inc is $17, above its last closing price of $7.06.
The company's guidance on August 4 2022 for the period ended
September 30 was for Earnings before Interest, Taxes,
Depreciation and Amortization of between 65.3 million and -4
million (USD).
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.09 -0.10 -0.03 Beat 70.2
Mar. 31 2022 -0.09 -0.11 -0.06 Beat 47.6
Dec. 31 2021 -0.16 -0.21 -0.19 Beat 10.2
Sep. 30 2021 -0.21 -0.22 -0.18 Beat 17.2
Jun. -0.14 -0.14 0.00 Beat 100
30 2021
Mar. 31 2021 -0.13 -0.15 -0.06 Beat 59.2
Dec. 31 2020 -0.17 -0.19 -0.16 Beat 17.1
Sep. 30 2020 -0.27 -0.27 -0.21 Beat 21.9
This summary was machine generated November 4 at 23:09 GMT. All
figures in US dollars unless otherwise stated